Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.

Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.

Item
http://www.wikidata.org/entity/Q35278325
Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens.The times they are a-changin': carbapenems for extended-spectrum-β-lactamase-producing bacteriaPharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.FosfomycinFosfomycin: Resurgence of an old companion.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Tackling antimicrobial resistance in lower urinary tract infections: treatment options.Editorial Commentary: Fosfomycin: The Current Status of the Drug.Fosfomycin: Pharmacological, Clinical and Future Perspectives.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?
P2860

Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.

Item
http://www.wikidata.org/entity/Q35278325
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@ast
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@en
type
label
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@ast
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@en
prefLabel
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@ast
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Fosfomycin versus meropenem in ...... n randomised controlled trial.
@en
P2093
P2860
P304
P31
P356
10.1136/BMJOPEN-2014-007363
P433
P478
P50
P577
P5875
P698
P932